ALVO
Alvotech Sa
NASDAQ · Biotechnology
$5.12
+0.13 (+2.61%)
Open$5.01
Previous Close$4.99
Day High$5.15
Day Low$4.98
52W High$13.08
52W Low$4.32
Volume—
Avg Volume341.8K
Market Cap1.53B
P/E Ratio22.02
EPS$0.21
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+519.5% upside
Current
$5.12
$5.12
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 548.91M | 146.14M | 133.98M |
| Net Income | -258,687,717 | 28.46M | 26.13M |
| Profit Margin | -47.1% | 19.5% | 19.5% |
| EBITDA | 10.34M | 50.85M | 43.53M |
| Free Cash Flow | — | 28.40M | 33.36M |
| Rev Growth | +131.4% | +3.3% | +20.0% |
| Debt/Equity | — | 0.48 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |